FDA Approves Neoadjuvant Pembro for Triple-Negative Breast Cancer ...Middle East

Medscape - News
The approval is based on phase 3 trial data showing prolonged event-free survival with the pembrolizumab regimen vs neoadjuvant chemotherapy alone for previously untreated stage II or III TNBC. FDA Approvals

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves Neoadjuvant Pembro for Triple-Negative Breast Cancer )

Apple Storegoogle play

Also on site :